Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)



Status:Recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/2/2016
Contact:Elta Field
Email:field-elta@cooperhealth.edu
Phone:856-325-6759

Use our guide to learn which trials are right for you!

Phase II Trial of Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Avastin is a novel antiangiogenic agent that has recently been shown to improve response
rates and survival of patients with advanced nonsquamous non-small cell lung cancer when
added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely
incorporated into the treatment of these patients. Alimta is a recently approved
chemotherapeutic that has shown activity against non-small cell lung cancer when given alone
and in combination with carboplatin, has a favorable toxicity profile andrequires only a
brief (10 minute) infusion time. Therefore we propose to study the combination of Avasin,
Alimta, and Carboplatin administered as front-line therapy to patients with advanced
nonsquamous non-small cell lung cancer.


Inclusion Criteria:

I am 18 years of age or older. I have advanced non-small lung cancer. I have not had any
major surgical procedures within 28 days prior to my starting treatment.

I have high blood pressure that is controlled. I am not on heparin, coumadin or lovonox
for treatment of medical conditions. I do not have serious wound healing problems. I have
not received any previous treatment, except radiation therapy for my disease.

Exclusion Criteria:
We found this trial at
1
site
Voorhees, New Jersey 08043
?
mi
from
Voorhees, NJ
Click here to add this to my saved trials